Morbi et tellus imperdiet, aliquam nulla sed, dapibus erat. Aenean dapibus sem non purus venenatis vulputate. Donec accumsan eleifend blandit. Nullam auctor ligula

Get In Touch

Quick Email
info.help@gmail.com
  • Home |
  • Novo Nordisk’s triple G candidate drives 20% weight loss in phase 2 trial in China

Novo Nordisk’s triple G candidate drives 20% weight loss in phase 2 trial in China

  • February 24, 2026

Novo Nordisk and its Chinese partner have reported up to 19.7% weight loss in patients who took their triple agonist for 24 weeks, illuminating a potential path forward for the Danish drugmaker as it tries to recover from yesterday’s CagriSema failure.

Leave A Comment

Fields (*) Mark are Required